Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1218 • ACR Convergence 2022
Prevalence and Impact of Widespread Pain and Fibromyalgia on Measurement of Disease Severity in Psoriatic Arthritis: Lessons from the CorEvitas Registry
Philip J Mease¹, Alexis Ogdie², Dimitrios Pappas³, George Reed⁴ and Joel Kremer⁵, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³CorEvitas, LLC, Waltham, MA, ⁴The Corrona Research Foundation and University of Massachusetts, Albany, NY, ⁵The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: Fibromyalgia (FM) occurs concomitantly with inflammatory rheumatic disease, including psoriatic arthritis (PsA), in up to 20% of patients and chronic widespread pain (CWP) in…
Abstract Number: 1496 • ACR Convergence 2022
Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met?
Sarah Yazji¹, Philip Helliwell², Andra Balanescu³, JUAN CANETE⁴, Emmanuelle Dernis⁵, Uta Kiltz⁶, Ying Ying Leung⁷, Ennio Lubrano⁸, Ana-Maria Orbai⁹, PENELOPE PALOMINOS¹⁰, Rossana Scrivo¹¹, Josef Smolen¹², Sandra Meisalu¹³, Maarten de Wit¹⁴, Laure Gossec¹⁵ and Laura Coates¹⁶, ¹University of Oxford, Oxford, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, ⁴Rheumatology Department, Hospital Clinic and IDIBAPS, Barcelona, Spain, ⁵LE MANS general hospital, LE MANS, France, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Rheumatology Department, Singapore General Hospital, Singapore, Singapore, ⁸Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ‘‘Vincenzo Tiberio’’, Università degli Studi del Molise, Campobasso, Italy, ⁹Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹⁰Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ¹¹Rheumatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy, Roma, Rome, Italy, ¹²Medical University of Vienna, Vienna, Austria, ¹³East Tallinn Central Hospital, Tallinn, Estonia, ¹⁴Patient research partner, Amsterdam, Netherlands, ¹⁵Sorbonne Université, Paris, France, ¹⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: The Minimal Disease Activity (MDA) criteria evaluate PsA disease activity and response to treatment and are defined as meeting ≥5 criteria: tender joint count…
Abstract Number: 1601 • ACR Convergence 2022
Female Psoriatic Arthritis Patients Show Differences in Treatment Response to IL12/23 Inhibition in Combination with or Without MTX Compared to Male – Results from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial
Michaela Koehm¹, Ann Christina Foldenauer², Tanja Rossmanith³, Herbert Kellner⁴, Uta Kiltz⁵, Juergen Rech⁶, Gerd Burmester⁷, David Kofler⁸, Jan Brandt-Juergens⁹, Stephanie Finzel¹⁰, Raoul Bergner¹¹, Maren Sieburg¹² and Frank Behrens¹³, ¹Rheumatology Goethe-University Frankfurt, Frankfurt Am Main, Germany, ²Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, ³Fraunhofer Institute for Translational Medicine & Pharmacology ITMP, Frankfurt, Germany, ⁴Schwerpunktpraxis für Rheumatologie und Gastroenterologie, Munich, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶University Clinic Erlangen, Erlangen, Germany, ⁷Charité University Medicine Berlin, Berlin, Germany, ⁸University of Cologne, Cologne, Germany, ⁹Rheumatologische Schwerpunktpraxis, Berlin, Germany, ¹⁰University of Freiburg, Freiburg, Germany, ¹¹Klinikum Ludwigshafen, Ludwigshafen, Germany, ¹²Rheumatologische Facharztpraxis, Magdeburg, Germany, ¹³Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany
Background/Purpose: Subgroup analysis from different clinical trials and real-world data suggest, that there are differences in baseline characteristics, clinical phenotypes, and treatment responses in female…
Abstract Number: 2112 • ACR Convergence 2022
Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Christopher Ritchlin¹, Philip J Mease², Wolf-Henning Boehncke³, John Tesser⁴, Soumya Chakravarty⁵, Emmanouil Rampakakis⁶, May Shawi⁷, Elena Schiopu⁸, Joseph Merola⁹, Iain B McInnes¹⁰ and Atul Deodhar¹¹, ¹Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ²Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ³Deptartment of Dermatology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland, ⁴Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁵Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁶McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸Michigan Medicine Rheumatology Clinic – Taubman Center, Ann Arbor, MI, ⁹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹⁰Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ¹¹Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Guselkumab (GUS) is associated with robust and sustained improvement in PsA signs and symptoms in subgroups of patients (pts) pooled from the phase 3…
Abstract Number: 2128 • ACR Convergence 2022
Consistent Long-Term Guselkumab Efficacy Across Psoriatic Arthritis Domains Irrespective of Baseline Patient Characteristics
Iain B McInnes¹, John Tesser², Elena Schiopu³, Joseph Merola⁴, Soumya Chakravarty⁵, Emmanouil Rampakakis⁶, Natalie Shiff⁷, Alexa Kollmeier⁸, Xie L Xu⁹, May Shawi¹⁰, Frederic Lavie¹¹, Paul Bird¹² and Philip J Mease¹³, ¹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ²Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ³Michigan Medicine Rheumatology Clinic – Taubman Center, Ann Arbor, MI, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁶McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁷Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, ⁸Janssen-Cilag, Research & Development, LLC, San Diego, CA, ⁹Janssen Research & Development, LLC, San Diego, CA, USA, San Marcos, CA, ¹⁰Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ¹¹The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, Paris, France, ¹²University of New South Wales, Sydney, Australia, ¹³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: In the phase 3 DISCOVER (D)-1 and D-2 studies, guselkumab (GUS) significantly improved joint symptoms, skin disease, enthesitis, dactylitis, physical function, and quality of…
Abstract Number: 2145 • ACR Convergence 2022
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Trials
Lars Erik¹, Kim Papp², Douglas White³, Cecilia Asnal⁴, Wenjing Lu⁵, Ahmed Soliman⁵, Byron Padilla⁶, Michael Chen⁵ and Andrew Ostor⁷, ¹Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ²K Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, ³Rheumatology Department, Waikato Hospital, and Waikato Clinical School, University of Auckland, Hamilton, New Zealand, ⁴Hospital Alemán, Buenos Aires, Argentina, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc., Waukegan, IL, ⁷Cabrini Hospital, Monash University & Emeritus Research, Melbourne, Australia
Background/Purpose: PsA is a chronic, systemic inflammatory disease with a variety of clinical manifestations including arthritis, enthesitis, and dactylitis and is associated with skin and…
Abstract Number: 0192 • ACR Convergence 2022
Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis
Laura Coates¹, Arthur Kavanaugh², Erin McDearmon-Blondell³, Arthur Mandelin⁴, Tianming Gao⁵ and William Tillett⁶, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ²University of California San Diego, La Jolla, CA, ³AbbVie, Inc., Mettawa, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵AbbVie, Inc., North Chicago, IL, ⁶Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: RAPID3 (Routine Assessment of Patient Index Data 3) is a disease activity index calculated from 3 patient-reported measures: physical function, pain, and patient global…
Abstract Number: 0401 • ACR Convergence 2022
Direct to Patient Screening of Psoriatic Arthritis: Clinical Findings and Outcomes of Patient-Driven Rheumatology Referrals
Megan Meier¹ and Jessica Walsh², ¹University of Utah, North Salt Lake, UT, ²University of Utah, Salt Lake City, UT
Background/Purpose: Diagnostic delays are common with psoriatic arthritis (PsA), and screening surveys for identifying at-risk patients are infrequently used in busy clinical practices. We previously…
Abstract Number: 1007 • ACR Convergence 2022
Metabolic Disorders and Abnormal Dietary Patterns and Their Association with Psoriatic Arthritis Activity: The Dietary Intervention in PsA (DIPSA) Study
Lihi Eder¹, Charlene Compher², Helen Emanoilidis³, Ryan F. Quinn², Dafna Gladman⁴, Vinod Chandran⁵, Jose Scher⁶ and Alexis Ogdie⁷, ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Pennsylvania, Philadelphia, PA, ³Women's College Hospital, Toronto, ON, Canada, ⁴Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁵Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁶New York University School of Medicine, New York, NY, ⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic Arthritis (PsA) is associated with obesity and its related metabolic abnormalities. The role of diet as an adjunct therapy in PsA remains unclear.…
Abstract Number: 1038 • ACR Convergence 2022
Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Ankylosing Spondylitis
Arthur Kavanaugh¹, Xenofon Baraliakos², Sheng Gao³, Warner Chen³, Kristen Sweet³, Soumya Chakravarty⁴, Qingxuan Song³, May Shawi⁵, Frank Behrens⁶ and Proton Rahman⁷, ¹University of California San Diego, San Diego, CA, USA, San Diego, CA, ²Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ³Janssen Research and Development, LLC, Spring House, PA, ⁴Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁵Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁶Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁷Memorial University, St. John's, NL, Canada
Background/Purpose: Despite overlapping symptoms, axial psoriatic arthritis (axPsA) and ankylosing spondylitis (AS) may be distinct disorders with differing clinical manifestations, genetic associations, and radiographic findings.1…
Abstract Number: 1234 • ACR Convergence 2022
Characterizing Imaging Phenotypes in PsA: The Effect of Age and Sex
Lihi Eder¹ and Kangping Cui², ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada
Background/Purpose: Musculoskeletal ultrasound (MSK-US) provides valuable information on disease phenotype in psoriatic arthritis (PsA). While age and sex are important determinants of health, limited information…
Abstract Number: 1497 • ACR Convergence 2022
How Does Time to Diagnosis and Gender Affect Treatment Outcomes in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? – Real World Data from a German Observational Study with Secukinumab
Karolina Benesova¹, Oliver Hansen², Uta Kiltz³, Jan Brandt-Juergens⁴, Peter Kästner⁵, Elke Riechers⁶, Daniel Peterlik⁷, Christina Budden⁷, Annika Boas⁷, Stefanie Welle⁷ and Hans-Peter Tony⁸, ¹University Hospital Heidelberg, Heidelberg, Germany, ²Medizinische Abteilung V - Rheumatologie, Universitätsklinikum, Heidelberg, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁵Ambulantes Rheumazentrum, Medizinisches Versorgungszentrum, Erfurt, Germany, ⁶Medizinische Hochschule Hannover, Hannover, Germany, ⁷Novartis Pharma GmbH, Nürnberg, Germany, ⁸Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany
Background/Purpose: In both, ankylosing spondylitis (AS) and psoriatic arthritis (PsA), women typically have a longer delay in diagnosis.1,2 There is scientific evidence that prognosis for…
Abstract Number: 1602 • ACR Convergence 2022
Fibroblast Activation Protein (FAP) PET-CT for Depicting Inflammatory Joint Damage in Patients with Psoriatic Arthritis
Simon Rauber¹, Hashem Mohammadian², Chrstian Schmidkonz³, Armin Atzinger³, Maria Gabriella Raimondo¹, Hannah Labinsky⁴, Christoph Treutlein², Johannes Knitza¹, Simone Maschauer², Frank Roemer⁵, Olaf Prante², Torsten Kuwert³, Juan Canete⁶, Georg Schett⁷ and Andreas Ramming¹, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²Friedrich-Alexander-University (FAU) Erlangen-Nürnberg, Erlangen, Germany, ³Friedrich-Alexander University (FAU) Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Friedrich-Alexander University Erlangen Nürnberg, Erlangen, Germany, ⁶Unidad de Artritis Hospital Clinic, Barcelona, Spain, ⁷Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Psoriatic arthritis (PsA) is characterized by substantial mesenchymal tissue activation in the context of inflammation leading to structural damage. Measuring mesenchymal tissue activation in…
Abstract Number: 2113 • ACR Convergence 2022
Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies
Dennis McGonagle¹, Derek Haaland², Philip Helliwell³, A. Marilise Marrache⁴, May Shawi⁵, Emmanouil Rampakakis⁶, Peter Nash⁷, Fedra Irazoque Palazuelos⁸ and Arthur Kavanaugh⁹, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²The Waterside Clinic, Oro Medonte, ON, Canada, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Janssen Inc., Dollard-des-Ormeaux, QC, Canada, ⁵Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁶McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁷School of Medicine, Griffith University, Sunshine Coast, Australia, ⁸Angeles Mocel Hospital; Universidad Autónoma de México, Ciudad de México, Mexico, ⁹University of California San Diego, La Jolla, CA
Background/Purpose: Despite available PsA treatments, a portion of PsA patients (pts) does not achieve improvements in PsA signs and symptoms according to ACR response criteria.…
Abstract Number: 2130 • ACR Convergence 2022
Apremilast in Bio-Naïve Patients with Early Psoriatic Arthritis: A National, Real-Life, Multicenter, Non-Interventional, Prospective, 52-week Cohort Study
Petros P. Sfikakis¹, Dimitrios Vassilopoulos², Gkikas Katsifis³, Georgios Vosvotekas⁴, Theodoros Dimitroulas⁵, Argyro Repa⁶, Grigorios Sakellariou⁷, THEODORA SIMOPOULOU⁸, Athanasios Georgountzos⁹, Andreas Bounas¹⁰, Panagiotis Georgiou¹¹, Evangelia Mole¹², Evangelia Kataxaki¹³, Stamatis Nick Liossis¹⁴, Evangelos Theodorou¹⁵, Christina Antoniadou¹⁶, EVANGELOS THEOTIKOS¹⁷, PANAYIOTIS VLACHOYIANNOPOULOS¹⁸, THEODORA MARKATSELI¹⁹, Angeliki Kekki²⁰, NIKOLAOS ANTONAKOPOULOS²¹ and Dimitrios Boumpas²², ¹Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, ²Clinical Immunology-Rheumatology Unit, 2nd Department of Internal Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece, ³Naval Hospital of Athens, Athens, Greece, ⁴Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ⁵4th Department of Internal medicine, Hippokration Hospital, School of medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece, Thessaloniki, Greece, ⁶Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Heraklion, Crete, Greece, ⁷Department of Rheumatology, 424 General Army Hospital, Thessaloniki, Greece, Thessaloniki, Greece, ⁸Clinic of Rheumatology and Clinical Immunology, University Hospital of Larissa, Larissa, Greece, Larissa, Larisa, Greece, ⁹General Hospital of Athens G. Gennimatas, Athens, Greece, ¹⁰Olympion private General Clinic of Patras, Patras, Greece;, Patra, Akhaia, Greece, ¹¹Rheumatology Unit, Agios Andreas Hospital, Patras, Greece, PATRA, Akhaia, Greece, ¹²Department of Rheumatology, KAT General Hospital of Attica, Athens, Greece, ¹³Rheumatology Unit, Thriasio General Hospital of Elefsina, Magoula, Greece, ¹⁴Division of Rheumatology, Department of Internal Medicine, Patras University Hospital, University of Patras Medical School, Patras, Greece, Patras, Akhaia, Greece, ¹⁵Rheumatology Clinic 251 Hellenic Air Force Hospital, Athens, Greece, ¹⁶First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece, ¹⁷Rheumatology Department, Asklepieion Voulas General Hospital, Athens, Greece, ¹⁸Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece, ¹⁹Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece, ²⁰Genesis Pharma SA, Halandri, Greece, ²¹Genesis Pharma SA, Chalandri, Greece, ²²4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Joint Academic Rheumatology Program, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Apremilast is a targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD) approved for psoriatic arthritis (PsA). Few clinical studies assessing treatment regimens in PsA have focused…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].